Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320824 · ClinicalTrials.gov registry record · NA
New Dermal Filler for Lip Augmentation
A NA study, sponsored by Galderma R&D.
- Completed
- Registry status
- NA
- Development phase
- 273
- Enrollment target
NCT03320824: Completed NA study, sponsored by Galderma R&D.
NCT03320824 is a NA study that has completed, run by Galderma R&D. The registered enrollment target is 273 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03320824, a NA study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 273 participants
- Enrollment target
Study Summary
To demonstrate non-inferiority of Kysse versus a control in lip fullness augmentation
Primary Outcome
The MLFS is a validated photograph-based outcome instrument that is designed specifically for quantifying lip fullness. Scoring of lip fullness (grades 0-5, with a higher score reflecting greater lip fullness) was based on visual live assessment by the Blinded Evaluator at defined time points, and not on a comparison to the baseline appearance. Effectiveness is defined as change from baseline at 8 weeks after last injection of New Dermal Filler or Dermal Filler (control).
Interventions
- DEVICE New Dermal Filler
- DEVICE Device: FDA Approved Dermal Filler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2019-04-23 |
| Phase | NA |
What the finished NCT03320824 record still lists
NCT03320824 is an interventional study that assigns participants to a tested intervention. The registered 273 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which New Dermal Filler is the first listed.
NCT03320824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03320824 about?
NCT03320824 is a clinical study titled "New Dermal Filler for Lip Augmentation". To demonstrate non-inferiority of Kysse versus a control in lip fullness augmentation
What is the current status of trial NCT03320824?
This trial is currently completed. It is a NA study. The enrollment target is 273 participants. The study started on 2017-11-13. Estimated completion is 2019-04-23.
What interventions are being tested in trial NCT03320824?
The interventions under investigation include: New Dermal Filler (DEVICE), Device: FDA Approved Dermal Filler (DEVICE).
Who is sponsoring clinical trial NCT03320824?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03320824's enrollment target sits among peer trials
273 386th of 2000 higher than 1,614 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07229430 · 273 participants · NA
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI